Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00717145 · ClinicalTrials.gov registry record · Phase 1
Food Effects on the Relative Bioavailability of Different Dosages of Risedronate
A Phase 1 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT00717145: Completed Phase 1 study, sponsored by Warner Chilcott.
NCT00717145 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00717145, a Phase 1 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment period), and exit procedures.
Interventions
- DRUG risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
What the finished NCT00717145 record still lists
NCT00717145 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 1 intervention - of which risedronate is the first listed.
NCT00717145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00717145 about?
NCT00717145 is a clinical study titled "Food Effects on the Relative Bioavailability of Different Dosages of Risedronate". Randomized, open-label, multi-center, 4-treatment, 4-period crossover study. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2, 3, and 4), 4 treatment periods (4 days each), 3 washout periods (14 to 17 days in duration separating each treatment per...
What is the current status of trial NCT00717145?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2008-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00717145?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00717145?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00717145's enrollment target sits among peer trials
94 615th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia